SK Biopharmaceuticals Co., Ltd. (KRX:326030)

SK Biopharmaceuticals Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 4, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	10,493,976	8,700,602	7,862,650	5,646,385	7,612,048	13,234,939
Market Cap Growth	19.64%	10.66%	39.25%	-25.82%	-42.48%	-
Enterprise Value	10,303,841	8,637,734	7,807,605	5,442,304	7,267,516	12,840,764
Last Close Price	134000.00	111100.00	100400.00	72100.00	97200.00	169000.00
PE Ratio	32.75	36.14	-	-	117.39	-
Forward PE	42.29	73.81	-	-	-	-
PS Ratio	15.54	15.89	22.16	22.94	18.18	509.06
PB Ratio	15.22	15.16	24.50	17.84	17.14	34.92
P/TBV Ratio	15.78	16.24	29.59	18.86	17.90	36.83
P/FCF Ratio	73.36	93.05	-	-	-	-
P/OCF Ratio	71.79	91.68	-	-	-	-
EV/Sales Ratio	15.26	15.77	22.00	22.11	17.36	493.89
EV/EBITDA Ratio	58.70	75.93	-	-	68.18	-
EV/EBIT Ratio	65.18	89.66	-	-	76.53	-
EV/FCF Ratio	72.03	92.38	-	-	-	-
Debt / Equity Ratio	0.07	0.32	0.56	0.49	0.04	0.05
Debt / EBITDA Ratio	0.23	1.62	-	-	0.15	-
Debt / FCF Ratio	0.35	1.97	-	-	-	-
Asset Turnover	0.75	0.62	0.51	0.38	0.73	0.08
Inventory Turnover	0.31	0.40	0.35	0.53	0.60	0.13
Quick Ratio	1.84	1.26	1.47	2.28	2.64	5.67
Current Ratio	2.43	1.64	2.02	2.99	3.18	6.16
Return on Equity (ROE)	58.15%	50.72%	-11.10%	-36.66%	15.75%	-135.18%
Return on Assets (ROA)	13.73%	6.84%	-3.38%	-12.53%	10.38%	-46.83%
Return on Capital (ROIC)	19.35%	9.58%	-4.83%	-17.57%	13.84%	-60.65%
Return on Capital Employed (ROCE)	25.90%	15.00%	-7.80%	-26.20%	19.20%	-55.70%
Earnings Yield	3.05%	2.77%	-0.42%	-2.47%	0.85%	-1.87%
FCF Yield	1.36%	1.07%	-1.23%	-2.92%	-1.28%	-1.68%
Buyback Yield / Dilution	-	-	-	-	-9.12%	-10.41%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.